Avecia and Barofold sign development and manufacturing agreement
US company BaroFold, developer of PreEMT protein processing technology, has entered into an agreement with Avecia Biologics for process development and cGMP manufacture of BaroFold's lead, proprietary compound, BaroFeron interferon beta-1b.
US company BaroFold, developer of PreEMT protein processing technology, has entered into an agreement with Avecia Biologics for process development and cGMP manufacture of BaroFold's lead, proprietary compound, BaroFeron interferon beta-1b.
The programme involves Avecia integrating operation of PreEMT technology alongside other stages of protein purification in both pilot and cGMP facilities. Avecia has both installed a PreEMT Plus system in its development laboratory and completed manufacture of BaroFeron.
Avecia will carry out development work to optimise and scale-up the drug manufacturing process for BaroFeron, using BaroFold's proprietary PreEMT protein processing technology.
Completing the scale-up of the drug manufacturing process will be a significant milestone, providing a platform to potentially expand the use of PreEMT technology to address areas of fundamental importance for protein manufacturing. BaroFold's technology potentially enables its corporate partners to develop next generation protein biologics to meet the need for safer and cost-effective new therapeutics.
"We are delighted to be working with BaroFold on development of a manufacturing process for BaroFeron," said Dr Stephen Taylor, Avecia's business director. "We are also excited that they have recognised Avecia's track record of technological innovation and have chosen to work with us on scale-up of the novel PreEMT technology."